Physician profile

Alex Diaz

Pulmonary Disease · San Ramon, CA

NPI 1659759363

$4,772.91

in general payments reported to CMS, 2019-2025

38 companies · $1,818 in 2025

The $1,818 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$3,779.14
Education$138.98

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $961.43 2022-2025 Nucala, Trelegy Ellipta, Arexvy
Astrazeneca Pharmaceuticals LP $860.60 2021-2025 Fasenra, Tezspire, Airsupra
Boehringer Ingelheim Pharmaceuticals, INC. $384.05 2021-2025 Ofev, Jascayd, Jardiance
Pulmonx Corporation $263.99 2024-2025 Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter
Genzyme Corporation $253.25 2021-2025
Insmed, INC. $217.01 2022-2024 Arikayce
Amgen INC. $211.80 2023-2025 Tezspire, Krystexxa
Inspire Medical Systems, INC. $198.13 2025 Inspire
Janssen Pharmaceuticals, INC $150.73 2021-2023 Xarelto
Regeneron Healthcare Solutions, INC. $140.79 2024-2025 Dupixent
Sanofi-Aventis U.S. LLC $138.98 2024-2025
Inari Medical, INC. $104.50 2025 Ct Thrombectomy System Kit, Flowtriever Catheter, S
Verona Pharma, INC. $77.30 2025 Ohtuvayre
Baxter Healthcare $71.18 2022-2025 Hillrom - Monarch Airway Clearance System, Hillrom - Vest System Model 105 Home Care
Takeda Pharmaceuticals U.S.A., INC. $70.22 2023-2025 Cuvitru, Glassia
Show all 38 companies
CompanyGeneral paymentsYearsTop products
Mallinckrodt Hospital Products INC. $67.00 2025 Acthar
Lundbeck LLC $66.42 2024-2025 Rexulti
Mylan Specialty L.P. $65.50 2021-2024 Yupelri
Philips North America LLC $47.79 2023-2025 Vest Therapy Und
Stryker Corporation $40.35 2025 Flowtriever
Alexion Pharmaceuticals, INC. $33.70 2025 Ultomiris
Exact Sciences Corporation $30.84 2024 Cologuard Collection Kit
Abiomed $29.30 2024 Impella
Abbvie INC. $27.03 2022
Nestle Healthcare Nutrition INC. $25.31 2023
Teva Pharmaceuticals USA, INC. $24.45 2022
La Jolla Pharmaceutical Company $22.96 2024 Giapreza
Edwards Lifesciences Corporation $22.21 2025 Edwards Sapien 3 Transcatheter Heart Valve (Thv)
Vivus LLC $21.97 2022
Ethicon INC. $20.38 2022
Biogen, INC. $19.28 2024 Spinraza
Neurocrine Biosciences, INC. $17.02 2022
Otsuka America Pharmaceutical, INC. $16.31 2023 Rexulti
Sumitomo Pharma America, INC. $15.81 2024 Gemtesa
Actelion Pharmaceuticals US, INC. $14.35 2023 Opsumit, Uptravi
Avanir Pharmaceuticals, INC. $13.84 2021
Gilead Sciences, INC. $13.69 2023 Veklury
Pfizer INC. $13.44 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Alex Diaz

$4,772.91

in general payments reported 2019-2025

Years
2021-2025
Top company
Glaxosmithkline, LLC.
Context
The $1,818 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).

https://glasscript.com/doctor/2785685/alex-diaz

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.